Chloroquine et Hydroxychloroquine dans le traitement de la COVID-19
Mouna Jameleddine ; Hela Grati ; Nabil Harzallah ; Marie Christine Jebali ; Chokri Hamouda
Record ID 32018000458
Authors' objectives: This rapid review was prepared in the context of the national emergency of COVID-19 outbreak. It provides an overview of recommendations and expert consensus as well as the current positions of several international organizations regarding the use of chloroquine and hydroxychloroquine in the treatment of COVID-19 in various contexts. In the circumstances of such public health emergency, INEAS provides health experts and decision-makers with as much scientific evidence as possible regarding the efficacy and safety of these drugsin the treatment of COVID-19 and remains on the lookout for any new data that could lead to changes in this document.
Authors' results and conclusions: To date, there is insufficient robust evidence from randomized clinical trials, which makes it impossible to have a clear position on the use of these two molecules in the treatment of COVID-19. This would explain the great heterogeneity of current practices in different countries.
Project Status: Completed
Year Published: 2020
URL for published report: http://www.ineas.tn/fr/actualite/chloroquine-et-hydroxychloroquine-dans-le-traitement-du-covid-19-revue-rapide-de-la
English language abstract: An English language summary is available
Publication Type: Rapid Review
- Clinical Trials as Topic
- Coronavirus Infections
- Pneumonia, Viral
- Treatment Outcome
- Drug Therapy
Organisation Name: National Authority for Assessment and Accreditation in Healthcare (INEAS)
Contact Address: 7 bis Rue Ahmed Rami 1002 le belvédère Tunis, Tunisie
Contact Name: Mouna Jameleddine
Contact Email: email@example.com
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.